SRZN
Surrozen·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 3
Stock Price Surged Significantly
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
RSI Overbought
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SRZN
Surrozen, Inc.
A company that pioneered targeted therapeutics for tissue repair and regeneration
171 Oyster Point Boulevard, Suite 400, South San Francisco, California
--
Surrozen, Inc., a biotech company incorporated in Delaware on August 21, 2020, is dedicated to discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to harness the body's existing bioremediation mechanisms for potential applications in a variety of disease areas, including intestinal, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas and central nervous system diseases.
Company Financials
EPS
SRZN has released its 2025 Q3 earnings. EPS was reported at -8.36, versus the expected -1.17, missing expectations. The chart below visualizes how SRZN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SRZN has released its 2025 Q3 earnings report, with revenue of 983.00K, reflecting a YoY change of -90.17%, and net profit of -71.64M, showing a YoY change of -4896.03%. The Sankey diagram below clearly presents SRZN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
